NPPB and Tako-tsubo cardiomyopathy: The clinical manifestations of CV damage in COVID-19 patients include myocarditis (including fulminant myocarditis) and pericarditis, hypertension, arrhythmias, myocardial injury (evidenced by elevated troponin, creatine kinase, NT-proBNP levels), and heart failure, coronary heart disease, stress cardiomyopathy (Takotsubo cardiomyopathy), stroke, blood coagulation abnormalities (coagulation evidenced by elevated level of D-dimer), and also dyslipidemia (13, 23).